BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#189 of 347

Douglas Tsao

HC Wainwright & Co. · Equity Research Analyst
EstablishedRating since 2021No new ratings since May 2025

Analyst rating accuracy & track record

Douglas Tsao is an equity research analyst at HC Wainwright & Co.. Bullish Whales has scored 114 of their stock calls across 19 companies. Their picks beat their sector 34% of the time over the next 12 months, and their price targets were reached 13% of the time within a year.

Win % vs sector
34%
PT Hit % (12mo)
13%
Avg sector-excess
−8.0%
Scored calls
114
Tickers
19
Tier
Established

Track record

Bullish Whales has scored 114 of Douglas Tsao's stock calls across 19 companies, dating back to 2021. Their rated stocks beat their own sector 34% of the time over the next 12 months. On a typical call, a Tsao pick returned −8.0% more than its sector over the following year.

Of the scored calls, 114 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
XENEXenon Pharmaceuticals Inc
Buy$53.00May 2025+71.9%Hit
CHRSCoherus BioSciences Inc
Buy$7.00Apr 2025+65.4%Miss
RZLTRezolute Inc
Buy$14.00Apr 2025−25.6%Miss
EOLSEvolus Inc
Buy$27.00Apr 2025−64.8%Miss
ARQTArcutis Biotherapeutics Inc
Buy$19.00Apr 2025+50.5%Hit
DAREDare Bioscience Inc
Buy$12.00Apr 2025−38.9%Miss
CABACabaletta Bio Inc
Buy$25.00Apr 2025+111.9%Miss
IMVTImmunovant Inc
Buy$51.00Mar 2025+18.6%Miss
CHRSCoherus BioSciences Inc
Buy$7.00Mar 2025+74.1%Miss
NMRANeumora Therapeutics, Inc.
Buy$18.00Mar 2025+134.0%Miss
EOLSEvolus Inc
Buy$27.00Mar 2025−63.0%Miss
NMRANeumora Therapeutics, Inc.
Buy$18.00Mar 2025+106.5%Miss
APLSApellis Pharmaceuticals Inc
Buy$57.00Mar 2025−27.2%Miss
TBPHTheravance Biopharma Inc
Buy$15.00Feb 2025+85.7%Hit
ARQTArcutis Biotherapeutics Inc
Buy$19.00Feb 2025+114.4%Hit
TBPHTheravance Biopharma Inc
Buy$15.00Feb 2025+101.3%Hit
OTLKOUTLOOK THERAPEUTICS INC
Buy$3.00Feb 2025−85.4%Hit
CABACabaletta Bio Inc
Buy$25.00Feb 2025+36.0%Miss
NMRANeumora Therapeutics, Inc.
Buy$30.00Feb 2025+93.8%Miss
EOLSEvolus Inc
Buy$27.00Feb 2025−81.1%Miss
RZLTRezolute Inc
Buy$14.00Feb 2025−27.5%Miss
APLSApellis Pharmaceuticals Inc
Buy$57.00Feb 2025−31.6%Miss
IMVTImmunovant Inc
Buy$51.00Feb 2025+29.7%Miss
IMVTImmunovant Inc
Buy$51.00Feb 2025+32.1%Miss
RZLTRezolute Inc
Buy$14.00Feb 2025−49.8%Miss
CHRSCoherus BioSciences Inc
Buy$7.00Jan 2025+55.1%Miss
EOLSEvolus Inc
Buy$27.00Jan 2025−75.6%Miss
IRONDisc Medicine Inc.
Buy$118.00Jan 2025+14.7%Miss
OTLKOUTLOOK THERAPEUTICS INC
Buy$30.00Jan 2025−88.3%Miss
CABACabaletta Bio Inc
Buy$25.00Jan 2025−26.7%Miss
APLSApellis Pharmaceuticals Inc
Buy$57.00Jan 2025−44.2%Miss
ARQTArcutis Biotherapeutics Inc
Buy$19.00Jan 2025+82.2%Hit
NMRANeumora Therapeutics, Inc.
Buy$30.00Jan 2025−47.6%Miss
ARQTArcutis Biotherapeutics Inc
Buy$19.00Dec 2024+86.4%Hit
DAREDare Bioscience Inc
Buy$12.00Dec 2024−39.2%Miss
IRONDisc Medicine Inc.
Buy$118.00Dec 2024+30.0%Miss
CHRSCoherus BioSciences Inc
Buy$7.00Dec 2024−26.5%Miss
OTLKOUTLOOK THERAPEUTICS INC
Buy$30.00Nov 2024−15.8%Miss
CABACabaletta Bio Inc
Buy$25.00Nov 2024−17.9%Miss
DAREDare Bioscience Inc
Buy$12.00Nov 2024−52.2%Miss
CABACabaletta Bio Inc
Buy$25.00Nov 2024−20.3%Miss
NMRANeumora Therapeutics, Inc.
Buy$30.00Nov 2024−84.6%Miss
RZLTRezolute Inc
Buy$14.00Nov 2024+66.6%Miss
IMVTImmunovant Inc
Buy$51.00Nov 2024−25.4%Miss
EOLSEvolus Inc
Buy$27.00Nov 2024−51.1%Miss
CHRSCoherus BioSciences Inc
Buy$12.00Nov 2024+65.4%Miss
APLSApellis Pharmaceuticals Inc
Buy$57.00Nov 2024−31.0%Miss
EOLSEvolus Inc
Buy$27.00Nov 2024−61.3%Miss
DAREDare Bioscience Inc
Buy$12.00Oct 2024−42.2%Miss
EOLSEvolus Inc
Buy$27.00Oct 2024−57.4%Miss
Go to

Douglas Tsao: analyst track record FAQ

Is Douglas Tsao a good stock analyst?

Yes, by track record. Douglas Tsao ranks number 189 of 347 of the analysts Bullish Whales scores, with a BW Score of 26 out of 100. Past results do not guarantee future ones.

What is Douglas Tsao's win rate?

Douglas Tsao's win rate is 34%. Across 114 scored calls, their rated stocks beat their sector 34% of the time over the next 12 months. On a typical call they returned −8.0% more than the sector.

What stocks and sectors does Douglas Tsao cover?

Douglas Tsao covers 19 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Douglas Tsao's price targets accurate?

Douglas Tsao's price targets are reached within 12 months 13% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Douglas Tsao's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Douglas Tsao rank among Wall Street analysts?

Douglas Tsao ranks number 189 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30